Welcome to Markets Desk, here's what's moving the needle right now.
A new antitrust lawsuit filed Friday in the Northern District of California is targeting four of the biggest names in artificial intelligence — Anthropic, OpenAI, SpaceX AI, and Google — alleging they coordinated a deliberate slowdown of AI development, effectively reducing the value of consumer subscriptions. If the claims hold, the legal exposure across those companies could be substantial, and it raises fresh questions about how Silicon Valley's AI race is actually being run behind closed doors.
Staying in the AI space, President Trump is vowing to create what he's calling an AI Force — a dedicated federal agency modeled closely on the Space Force he established during his first term. The proposal is framed as a national security imperative, aimed at protecting American dominance in artificial intelligence as competition with China intensifies. Details on structure and funding remain thin, but the signal to markets is clear.
Meanwhile, Teva Pharmaceutical is getting a moment in the spotlight after presenting positive post-hoc data from its Phase three SOLARIS trial for TEV-seven forty nine, a schizophrenia treatment now targeting an FDA decision in the fourth quarter of two thousand twenty six. Post-hoc data carries caveats, but the market will watch closely as Teva works to build out its branded pipeline beyond generics.
That's the tape. Markets Desk, signing off the floor.
